Tolu Onuwe

Tolu Onuwe

Auto-generated profile, based on publicly available information

Tolu Onuwe

Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester LE5 4PW, UK; National Institute for Health and Care Research Applied Research Collaboration East Midlands, Leicester, UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
GKGhanshyam Kacha
Ghanshyam Kacha
PHPatrick J. Highton
Patrick J. Highton
MFMark P. Funnell
Mark P. Funnell
CGClare Gillies
Clare Gillies
TOTolu Onuwe
Tolu Onuwe
KKKamlesh Khunti
Kamlesh Khunti
Despite advancements in diabetes management, adherence to HbA1c, blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) targets remains suboptimal. This review presents an updated meta-analysis of the achievement of these guideline targets globally in individuals with type 2 diabetes. This study included studies from 2017 to 2025, supplementing our prior meta-analysis covering 2006-2017. Observational studies assessing adherence to HbA1c, BP, and LDL-C targets and a combined target attainment were included. Random-effects meta-analysis was used to estimate pooled proportions, and meta-regression assessed the impact of study characteristics on target achievement. A total of 63 studies from 2006 to 2025, encompassing 1,618,972 patients, were included. Overall, 44% (95% CI: 41-48%) of individuals achieved HbA1c targets, 41% (95% CI: 34-47%) achieved BP targets, and 47% (95% CI: 42-51%) achieved LDL-C targets. Only 12% (95% CI: 7-16%) of individuals met all three targets simultaneously. Meta-regression analysis revealed no significant improvement in HbA1c target attainment from 1997 to 2023 in Europe and North America. Despite advances in pharmacotherapy, the achievement of targets for risk factor control in type 2 diabetes remains alarmingly low, with little progress over time. This review highlights the urgent need to address barriers in achieving guideline targets.

5 April 2025 in Diabetic Medicine
Verified
Journal Article
Open access
TOTolu Onuwe
Tolu Onuwe
PHPatrick J. Highton
Patrick J. Highton
DBDavid Batchelor
David Batchelor
ABAlan Brennan
Alan Brennan
MCMolly Caba
Molly Caba
KKKamlesh Khunti
Kamlesh Khunti
Background: In the United Kingdom, the prevalence of diabetes‐related foot ulcer disease (DFUD) is 6.3%, and cardiovascular disease (CVD) is the leading cause of mortality in people with DFUD. This study aims to evaluate the effectiveness of a multifactorial intervention to reduce CVD events and mortality in adults with type 2 diabetes (T2D) and DFUD. Methods: The MiFoot study is a multi‐centre, pragmatic randomised controlled trial to test intervention effectiveness and cost‐effectiveness compared to usual care that will include an internal feasibility study and a process evaluation. English‐speaking adults (≥18 years; n = 392) with T2D and current/previous (within 5 years) DFUD will be recruited from multiple sites across the United Kingdom and randomised 1:1 to intervention (MiFoot multifactorial intervention plus usual care) or control (usual care), with data collected at baseline, 12‐ and 24‐month follow‐up. The MiFoot intervention comprises an individualised assessment with a healthcare practitioner to optimise treatment and assess the suitability of physical activity participation; group‐based disease self management education and physical activity sessions; and a digital‐based programme, consisting of cohort‐relevant topics, physical activity guidance and peer support functionality. The primary outcome will be extended major adverse cardiovascular events (MACE, i.e. myocardial infarction, stroke, cardiovascular death, peripheral arterial bypass, coronary artery bypass, coronary angioplasty or peripheral artery angioplasty) at 24 months. DISCUSSION: This study will provide evidence on the feasibility and clinical effectiveness, and cost‐effectiveness of a multifactorial intervention to prevent or slow the progression of CVD‐related complications in the extremely high‐risk population with T2D and DFUD.